Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$2.51 USD
+0.01 (0.40%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $2.52 +0.01 (0.40%) 6:48 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Allogene Therapeutics, Inc. [ALLO]
Reports for Purchase
Showing records 1 - 20 ( 215 total )
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initial Cema-cel Data in CLL and Updated ALLO-316 Data Expected Later This Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ALLO-501A Pivots Into 1L LBCL and Expands Into R/R CLL; Modulating PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Genomic Medicine Deep Dive-Redrawing Frontiers at the Coding Level
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ALLO-182 Preclinical Data Presented; 3Q23 Financials; Lowering PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R